Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2020 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline
- PMID: 32956597
- DOI: 10.7326/M20-4648
Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2020 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline
Abstract
Description: In June 2020, the U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) released a joint update of their clinical practice guideline for managing dyslipidemia to reduce cardiovascular disease risk in adults. This synopsis describes the major recommendations.
Methods: On 6 August to 9 August 2019, the VA/DoD Evidence-Based Practice Work Group (EBPWG) convened a joint VA/DoD guideline development effort that included clinical stakeholders and conformed to the Institute of Medicine's tenets for trustworthy clinical practice guidelines. The guideline panel developed key questions, systematically searched and evaluated the literature (English-language publications from 1 December 2013 to 16 May 2019), and developed 27 recommendations and a simple 1-page algorithm. The recommendations were graded by using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system.
Recommendations: This synopsis summarizes key features of the guideline in 7 crucial areas: targeting of statin dose (not low-density lipoprotein cholesterol goals), additional tests for risk prediction, primary and secondary prevention, laboratory testing, physical activity, and nutrition.
Comment in
-
The U.S. Department of Veterans Affairs and U.S. Department of Defense Guideline for the Management of Dyslipidemia: Is Moderate Risk Reduction Enough?Ann Intern Med. 2020 Nov 17;173(10):846-847. doi: 10.7326/M20-6125. Epub 2020 Sep 22. Ann Intern Med. 2020. PMID: 32956605 No abstract available.
-
Dyslipidemia Management for Cardiovascular Disease Prevention: Guidelines from the VA/DoD.Am Fam Physician. 2021 Apr 15;103(8):507-509. Am Fam Physician. 2021. PMID: 33856172 No abstract available.
Similar articles
-
Management of dyslipidemia for cardiovascular disease risk reduction: synopsis of the 2014 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline.Ann Intern Med. 2015 Aug 18;163(4):291-7. doi: 10.7326/M15-0840. Ann Intern Med. 2015. PMID: 26099117
-
The Management of Substance Use Disorders: Synopsis of the 2021 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline.Ann Intern Med. 2022 May;175(5):720-731. doi: 10.7326/M21-4011. Epub 2022 Mar 22. Ann Intern Med. 2022. PMID: 35313113
-
The Use of Opioids in the Management of Chronic Pain: Synopsis of the 2022 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline.Ann Intern Med. 2023 Mar;176(3):388-397. doi: 10.7326/M22-2917. Epub 2023 Feb 14. Ann Intern Med. 2023. PMID: 36780654
-
Synopsis of the 2020 US Department of Veterans Affairs/US Department of Defense Clinical Practice Guideline: The Non-Surgical Management of Hip and Knee Osteoarthritis.Mayo Clin Proc. 2021 Sep;96(9):2435-2447. doi: 10.1016/j.mayocp.2021.03.017. Mayo Clin Proc. 2021. PMID: 34481599 Review.
-
Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) guidelines for management of dyslipidemia and cardiovascular disease risk reduction: Putting evidence in context.Prog Cardiovasc Dis. 2021 Sep-Oct;68:2-6. doi: 10.1016/j.pcad.2021.08.001. Epub 2021 Aug 8. Prog Cardiovasc Dis. 2021. PMID: 34371083 Review.
Cited by
-
Association of HMGCR rs17671591 and rs3761740 with lipidemia and statin response in Uyghurs and Han Chinese.PeerJ. 2024 Sep 27;12:e18144. doi: 10.7717/peerj.18144. eCollection 2024. PeerJ. 2024. PMID: 39351366 Free PMC article.
-
Assessment of Albumin-Incorporating Scores at Hepatocellular Carcinoma Diagnosis Using Machine Learning Techniques: An Evaluation of Prognostic Relevance.Bioengineering (Basel). 2024 Jul 28;11(8):762. doi: 10.3390/bioengineering11080762. Bioengineering (Basel). 2024. PMID: 39199720 Free PMC article.
-
A pharmacovigilance study of chronic kidney disease in diabetes mellitus patients with statin treatment by using the US Food and Drug Administration adverse event reporting system.Front Pharmacol. 2024 Jun 21;15:1363501. doi: 10.3389/fphar.2024.1363501. eCollection 2024. Front Pharmacol. 2024. PMID: 38974040 Free PMC article.
-
Response.Can Fam Physician. 2024 Jun;70(6):371. doi: 10.46747/cfp.7006371_1. Can Fam Physician. 2024. PMID: 38886080 Free PMC article. No abstract available.
-
Associations between remnant cholesterol levels and mortality in patients with diabetes.World J Diabetes. 2024 Apr 15;15(4):712-723. doi: 10.4239/wjd.v15.i4.712. World J Diabetes. 2024. PMID: 38680693 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical